Jnana Therapeutics Inc., a Boston-based startup building a drug discovery platform targeting a family of proteins that serve as cellular "metabolic gates," has raised a $50 million series A financing backed by Polaris Partners, Avalon Ventures, Versant Ventures, Abbvie Ventures LLC and Pfizer Inc.